May 16, 2022 Liver transplantation for patients with ACLF: The knowns and unknowns EF Clif Scientific Director, Rajiv Jalan, presented progress of the CHANCE study at ILTS 2022

A special session at the ILTS 2022 focused on acute-on-chronic liver failure prognosis and put liver transplantation and organ allocation policy into perspective. An event hosted by ILTS President Marina Berenger (Hospital Universitario La Fe, Spain) and Program Chair, ILTS President-elect Mohamed Rela (Dr. Rela Institute and Medical Center, India), where Rajiv Jalan presented the design and progress of the CHANCE study.

The International Congress of ILTS, ELITA and LICAGE 2022 took place on 4–7 May in Istambul, Turkey. With the theme “Promoting Excellence in Liver Transplantation" this event reviewed multidisciplinary scientific advances in liver transplantation worldwide.

Program >

Download (2,541 KB) >

About the CHANCE study

CHANCE is a multicenter, global, observational study designed to assess the benefit of liver transplantation in patients with acute-on-chronic liver failure (ACLF) grade 2 or grade 3. This study counts with the support of the International Liver Transplantation Society (ILTS) and the European Liver and Intestine Transplant Association (ELITA) to recruit 2000 patients in 80 centers in 27 countries around the world. The primary objective of the CHANCE study is to compare 1-year graft and patient survival rates after liver transplantation in patients with ACLF grade 2 or grade 3 at the time of liver transplantation with patients with decompensation of cirrhosis without ACLF-2 or 3 and transplant-free survival of patients with ACLF-2 or 3 not listed for liver transplantation. The international nature of this study will allow for deep assessments of the potential impact of different precipitating factors of ACLF (e.g., alcohol vs. Hepatitis B virus flare), different types of liver transplantation (deceased donor vs. living donor liver transplantation) and different regional and national allocation systems on transplant outcomes. Beside these clinical objectives, the CHANCE study aims to build a repository of biological samples to explore new biomarkers to predict prognosis on the waiting list and after liver transplantation, and mechanisms of liver and extrahepatic organ recovery.

ClinicalTrials.gov Identifier: NCT04613921

About EF Clif

The European Foundation for the Study of Chronic Liver Failure (EF Clif) is a private nonprofit organization which mission is to promote research and education in hepatic chronic failure with the aim to contribute to improving the quality of life and to increase the survival of patients with liver cirrhosis. Since its foundation in 2009, the European Association for the Study of the Liver (EASL) Chair supports research activities through the EASL-Clif Consortium, a network of more than 100 European university hospitals and more than 300 clinical researchers. The Grifols Chair promotes translational studies across centers throughout Europe and North America within the framework of the European Network for Translational Research (ENTR) with 25 centers and more than 40 investigators.

Download attached document (2,48 MB)